Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. News
  7. Summary
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:04 2022-08-05 pm EDT
49.27 USD   -1.18%
02:53aValneva Bets On Lyme Disease Jab As Climate Change Triggers Higher Cases
MT
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
12:12aMyovant Sciences-Pfizer's Once-daily Endometriosis Drug Obtains US FDA Nod
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

--Street Color: Pfizer, BioNTech Reportedly Will Receive $3.2 Billion From US Government to Produce Extra Covid-19 Vaccines, Bloomberg Says

06/29/2022 | 04:58pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.48% 183.11 Delayed Quote.-28.97%
PFIZER, INC. -1.18% 49.27 Delayed Quote.-16.56%
All news about PFIZER, INC.
02:53aValneva Bets On Lyme Disease Jab As Climate Change Triggers Higher Cases
MT
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
12:12aMyovant Sciences-Pfizer's Once-daily Endometriosis Drug Obtains US FDA Nod
MT
08/07Pfizer Nears $5 Billion Deal to Purchase Global Blood Therapeutics
MT
08/05Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treat..
AQ
08/05Myovant Sciences  and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily..
CI
08/05Pfizer In Advanced Talks to Acquire Global Blood Therapeutics for $5 Billion, WSJ Says
MT
08/05Pfizer in advanced talks to buy Global Blood Therapeutics for $5 bln - WSJ
RE
08/05Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
RE
08/05PFIZER IN ADVANCED TALKS TO BUY GLOB : Dow Jones
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 34 008 M - -
Net cash 2022 11 522 M - -
P/E ratio 2022 8,63x
Yield 2022 3,29%
Capitalization 276 B 276 B -
EV / Sales 2022 2,61x
EV / Sales 2023 3,30x
Nbr of Employees 79 000
Free-Float 58,9%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 49,27 $
Average target price 56,53 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-16.56%276 449
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068
NOVO NORDISK A/S2.86%233 797